News
Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy. The study — published May 11 in the New England Journal of Medicine — followed 751 people across the U.
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...
The Trump administration is pushing for reduced prices on weight-loss drugs like Wegovy and Zepbound, citing stark pricing ...
The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...
Weight loss drug stocks like Novo Nordisk have dropped significantly lately. This presents potential value opportunities in a market projected to grow to $105 billion by 2035. Skye Bioscience's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback